Biopharma gets better chance to protect patents during inter partes review

The USPTO launched a pilot program that gives patent owners additional opportunities to amend the scope of patent claims during inter partes review proceedings. The pilot amendment process affords the biopharma industry more flexibility in protecting their patent claims from invalidation during IPR.